Position in ZYME
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Derivatives in ZYME
reported options exposure · as of Mar 31, 2026CallValue
$1,327,120
CallShares
53,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026DLD Asset Management, LP holds $2,479,158 across 1 Biotechnology name.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
47,025 | $2,479,158 |
All Filings in ZYME
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,327,120 | 53,000 | Call | Sole | 2026-05-13 | |
| 2025-12-31 | $1,542,938 | 58,600 | Put | Sole | 2026-02-13 | |
| 2025-12-31 | $1,632,460 | 62,000 | Call | Sole | 2026-02-13 | |
| 2025-09-30 | $341,600 | 20,000 | Shares | Sole | 2025-11-14 | |
| 2025-09-30 | $903,532 | 52,900 | Call | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||